Table 1.
Baseline characteristics of the study population.
| Characteristics | Intensive treatment (N = 66) | Standard treatment (N = 50) | p Value |
|---|---|---|---|
| Age (years), median (IQR) | 66.0 (62.0–70.0) | 63.5 (61.0–69.0) | .278 |
| Male sex, N (%) | 28 (42.4) | 15 (30.0) | .170 |
| Body‐mass index (kg/m2), median (IQR) | 24.8 (23.2–27.2) | 24.4 (22.4–24.3) | .181 |
| Body surface area, m2 | 1.4 ± 0.5 | 1.6 ± 0.2 | .064 |
| Smoking status, N (%) | |||
| Current smoker | 6 (9.1) | 5 (10.0) | .981 |
| Former smoker | 5 (5.1) | 4 (8.0) | |
| Never smoker | 55 (83.3) | 41 (82.0) | |
| Heart rate, bpm | 72 (67–78) | 73 (66–77) | .592 |
| Blood pressure, mm Hg | |||
| Systolic | 140.2 ± 14.5 | 140.9 ± 12.7 | .791 |
| Diastolic | 83.0 ± 9.6 | 82.4 ± 8.4 | .730 |
| Distribution of systolic blood pressure, N (%)* | |||
| ≤135 mmHg | 24 (36.4) | 15 (30.0) | .770 |
| 136–147 mmHg | 22 (33.3) | 18 (36.0) | |
| ≥148 mmHg | 20 (30.3) | 17 (34.0) | |
| Duration of hypertension, year | 10.0 (5.0–15.0) | 10.5 (6.0–16.0) | .543 |
| Fasting serum glucose (mmol/L), median (IQR) | 5.51 (5.10–6.50) | 5.57 (5.01–6.60) | .804 |
| Creatinine, mg/dL | 0.83 (0.72–0.94) | 0.79 (0.68–0.98) | .380 |
| eGFR, mL/min per 1.73 m2 | 103.17 ± 21.42 | 104.00 ± 21.50 | .836 |
| Renal dysfunction, N (%) | 2 (3.0%) | 1 (2.0%) | .729 |
| Lipid profile, mmol/L | |||
| Total cholesterol | 4.87 ± 1.10 | 5.08 ± 0.96 | .291 |
| Triglycetides, median (IQR) | 1.28 (0.92–2.04) | 1.46 (1.00–1.99) | .352 |
| High‐density lipoprotein cholesterol, median (IQR) | 1.14 (1.01–1.47) | 1.20 (1.07–1.49) | .254 |
| Low‐density lipoprotein cholesterol | 2.69 ± 0.86 | 2.69 ± 0.81 | .995 |
| Comorbidity, N (%) | |||
| Diabetes mellitus | 14 (21.2) | 15 (30.6) | .269 |
| Hyperlipidemia | 27 (40.9) | 24 (49) | .565 |
| Cardiovascular disease, N (%) | 5 (7.6) | 4 (8.0) | .933 |
| Medication history, N (%) | |||
| Use of antihypertensive agents | 65 (98.5) | 49 (98.0) | .843 |
| Use of hypoglycemic agents | 11 (16.7) | 15 (30.0) | .088 |
| Use of lipid‐lowering drugs | 19 (28.8) | 16 (32.0) | .709 |
| Use of antiplatelet drugs | 7 (10.6) | 5 (10.0) | .915 |
| No. of antihypertensive agents | 1.6 ± 0.6 | 1.4 ± 0.6 | .088 |
*p < .05 was considered statistically significant.
Abbreviations: IQR, interquartile range.